Welcome! - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Welcome!


Pharmaceutical Technology Europe
Volume 24, Issue 6


Dr Jo Watts
It is with real pleasure that I join the Pharmaceutical Technology Europe (PTE) team. I am honoured to be the Editor of this magazine, especially at such an exciting time. This year celebrates the 35th anniversary of the Pharmaceutical Technology brand, an event that will be celebrated with special feature articles that evaluate the last three and a half decades of developments in the pharmaceutical industry (be sure to check out http://PharmTech.com/ in July for the celebratory retrospectives).

Given the current economic climate, none of us can foresee what the future holds for the industry, but our editorial team will endeavour to continue bringing you relevant, topical and unbiased information. As Editor, I will undertake providing you with engaging, enjoyable content that you will find both interesting and beneficial.

I look forward to meeting some of you at industry events in the coming months and hearing your views on what we can do to make your job easier. We welcome your feedback and participation in our online PharmTechGroup communities on LinkedIn and Twitter.

This month also sees the next ACHEMA event. In current economic times such shows can seem a financial burden, but the chance to meet people face-to-face is becoming less frequent, and to have such large numbers from the industry all under one roof is a compelling enough reason to attend. This year, the majority of the PTE team will be attending the show in Frankfurt. Visit us in hall 3.1, stand J25. You are more than welcome to visit us to let us know what's happening in your corner of the market, or to tell us about something exciting you've seen.

I would like to thank you, European Pharmaceutical Technologists, for your continued support of PTE over the years. With your constant input we will go on making PTE the successful magazine that it is.

Many thanks and best wishes,
Jo Watts, Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here